A kind of fucus polysaccharide-ellagic acid solid dispersion and its preparation method and application

Through the composite preparation of etocyanida polysaccharide and ellagic acid, ultrasonic assisted stirring and ball milling treatment, the problem of low absorption and utilization efficiency of ellagic acid was solved, significantly improved its transformation ability and biological activity in the gastrointestinal tract, and achieved More efficient health effects.

CN118634217BActive Publication Date: 2024-12-03SHENZHEN XIANGGAN SCIENCE & TECHNOLOGY ACHIEVEMENTS TRANSFORMATION CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410655895.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-05-24
Publication Date
2024-12-03
Estimated Expiration
2044-05-24

Smart Images

  • Figure CN118634217B_ABST
    Figure CN118634217B_ABST
Patent Text Reader

Abstract

The invention discloses a fucus polysaccharide-ellagic acid solid dispersion and a preparation method and application thereof, and relates to the technical field of natural product chemistry. The present invention uses the natural substance fucus polysaccharide as a carrier to prepare a fucus polysaccharide-ellagic acid solid dispersion, which can significantly improve the equilibrium solubility and dispersibility of ellagic acid, and at the same time improve the ability of ellagic acid to be converted into urolithin. The present invention has low preparation cost, simple process, is suitable for industrial scale, and is conducive to promoting the development of ellagic acid health food.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of natural product chemistry, and in particular to a fucus polysaccharide-ellagic acid solid dispersion and a preparation method and application thereof. Background Art

[0002] Ellagic acid is a natural polyphenol dilactone widely found in fruits or nuts such as pomegranates, blueberries, pecans, chestnuts, etc. A large amount of clinical and animal experimental data have fully confirmed that ellagic acid has multiple biological activities such as antioxidant, anti-inflammatory, anti-cancer, regulating intestinal flora and preventing chronic diseases, and has good biosafety. However, studies have shown that the absorption and utilization efficiency of ellagic acid in the gastrointestinal tract is extremely low, and it often needs to be converted into urolithin substances by intestinal flora before it can exert a health effect. Due to the difference in intestinal flora between individuals, there are obvious individual differences in its biological activity. Studies have shown that the increase in the solubility of ellagic acid will increase its ability to be converted into urolithin, such as: in an in vitro fermentation experiment, by adding 1% DMSO (dimethyl sulfoxide) to the culture medium, the solubility of ellagic acid in the culture medium can be increased, thereby improving its metabolic conversion process and increasing the conversion rate of the metabolite urolithin. However, compared with directly adding a solvent that dissolves ellagic acid, it is safer and more effective to prepare a loading system.

[0003] Therefore, there is an urgent need to propose a widely applicable method to increase the solubility of ellagic acid and at the same time improve the ability of ellagic acid to be converted into urolithin.

[0004] In view of this, the present invention is proposed. Summary of the invention

[0005] The purpose of the present invention is to provide a fucus polysaccharide-ellagic acid solid dispersion and a preparation method and application thereof, aiming to significantly improve the ability of ellagic acid to be converted into urolithin or to be used in ellagic acid solubilization.

[0006] The present invention is achieved in that:

[0007] In a first aspect, the present invention provides a fucan-ellagic acid solid dispersion, which is obtained by compounding a carrier and ellagic acid, wherein the carrier is fucan.

[0008] In an optional embodiment, the mass ratio of ellagic acid to fucus polysaccharide is 1:(0.2-5); preferably 1:(0.3-3).

[0009] In a second aspect, the present invention provides a method for preparing the fucan-ellagic acid solid dispersion according to any one of the aforementioned embodiments, comprising: preparing the solid dispersion using ellagic acid and fucan as raw materials.

[0010] In an optional embodiment, the method comprises: mixing ellagic acid and fucan polysaccharide with a solvent respectively to obtain an ellagic acid suspension and a fucan polysaccharide solution, mixing the ellagic acid suspension and the fucan polysaccharide solution, stirring the mixture under ultrasound-assisted conditions, and then ball milling the mixture, and removing the solvent after ball milling to obtain a powdered solid material;

[0011] Preferably, the Fucus polysaccharide is obtained by water extraction and purification of Fucus vesiculosus and meets the following characteristics:

[0012] Characteristics (1): Mainly composed of →4)-β-D-Manp-(1→, →3)-α-D-Fucp-(1→, α-D-Manp-(1→, →3)-β-D-Manp-(1→ and →4,6)-α-D-Manp-(1→ glycosidic bonds;

[0013] Feature (2): The total sugar content is 90%-99%, of which the main monosaccharides are fucose, xylose, mannose, glucuronic acid, glucose and galactose;

[0014] Feature (3): The average molecular weight is 30-35 kDa.

[0015] In an optional embodiment, the ellagic acid suspension and the fucose polysaccharide solution are mixed and stirred at 40° C.-50° C. for 2 h-6 h;

[0016] Preferably, during the stirring process, the ultrasonic power is controlled to be 100W-300W.

[0017] In an optional embodiment, the concentration of the ellagic acid suspension is 0.1 mg / mL-0.5 mg / mL, and the concentration of the fucus polysaccharide solution is 0.5 mg / mL-2.0 mg / mL;

[0018] Preferably, the solvent used in preparing the fucus polysaccharide solution is water, and the solvent used in preparing the ellagic acid suspension is an ethanol aqueous solution, wherein the volume fraction of ethanol in the ethanol aqueous solution is 40%-70%.

[0019] In an optional embodiment, the ball milling speed is controlled to be 100 rpm-200 rpm, and the ball milling time is 2 h-6 h;

[0020] Preferably, the solvent is removed by rotary evaporation.

[0021] In an optional embodiment, the powdered solid material is dried and then sieved to obtain a fucan-ellagic acid solid dispersion;

[0022] Preferably, the drying temperature is controlled to be 40°C-60°C, and the drying time is 4h-10h.

[0023] In a third aspect, the present invention provides a fucan-ellagic acid solid dispersion according to any of the aforementioned embodiments or a fucan-ellagic acid solid dispersion prepared by the preparation method according to any of the aforementioned embodiments for improving the ability of ellagic acid to be converted into urolithin or for use in solubilizing ellagic acid.

[0024] In a fourth aspect, the present invention provides an ellagic acid product, including the fucan-ellagic acid solid dispersion in the above embodiment or the fucan-ellagic acid solid dispersion prepared by the preparation method in the above embodiment.

[0025] The present invention has the following beneficial effects: the present invention uses the natural substance fucan as a carrier to prepare a fucan-ellagic acid solid dispersion, which can significantly improve the solubility of ellagic acid in water, enhance its suspension ability in water, reduce its degree of crystallization, and at the same time improve the ability of ellagic acid to be converted into urolithin. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0027] Figure 1 The equilibrium solubility diagrams are for ellagic acid, physical mixing of fucan and ellagic acid, preparation of fucan-ellagic acid solid dispersion by ball milling, and preparation of fucan-ellagic acid solid dispersion by ultrasonic treatment and solvent-ball milling, where different letters represent statistically significant differences in the data;

[0028] Figure 2 This is a graph showing the content of urolithin A produced by in vitro fermentation of ellagic acid, physical mixing of fucan and ellagic acid, preparation of fucan-ellagic acid solid dispersion by ball milling, and preparation of fucan-ellagic acid solid dispersion by ultrasonic treatment and solvent-ball milling. Different letters represent statistically significant differences in the data. DETAILED DESCRIPTION

[0029] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0030] The embodiment of the present invention provides a method for preparing a solid dispersion of fucose-ellagic acid, using fucose as a carrier. Fucose has the advantages of being green and natural, and it has been reported that fucose is beneficial to human intestinal health. By preparing a solid dispersion of fucose-ellagic acid, the solubility and dispersibility of ellagic acid in water can be significantly improved. The preparation process is as follows:

[0031] S1. Dissolution

[0032] The ellagic acid and the solvent are mixed to obtain an ellagic acid suspension, and the fucus vesiculosus polysaccharide and the solvent are mixed to obtain a fucus vesiculosus polysaccharide solution for later use.

[0033] Specifically, ellagic acid and Fucus vesiculosus can both be commercially available raw materials, such as ellagic acid can be an ellagic acid product produced by Xi'an Mixianer Biotechnology Co., Ltd., and Fucus vesiculosus polysaccharide can be a polysaccharide obtained by extracting and purifying the Fucus vesiculosus raw material provided by Qingdao Fuxingxiang Import and Export Co., Ltd. Fucus vesiculosus polysaccharide meets the following characteristics:

[0034] Feature (1): It is mainly composed of glycosidic bonds such as →4)-β-D-Manp-(1→, →3)-α-D-Fucp-(1→, α-D-Manp-(1→, →3)-β-D-Manp-(1→ and →4,6)-α-D-Manp-(1→); Feature (2): The total sugar content is 90%-99%, among which the main monosaccharides are fucose, xylose, mannose, glucuronic acid, glucose and galactose; Feature (3): The average molecular weight is 30-35kDa.

[0035] Generally speaking, ellagic acid is slightly soluble in organic solvents, and fucus polysaccharide is soluble in water. In some embodiments, the solvent used to prepare the ellagic acid suspension is an ethanol aqueous solution, and the volume fraction of ethanol in the ethanol aqueous solution is 40%-70%, which can better suspend ellagic acid and allow the reaction to proceed fully.

[0036] Further, the concentration of the ellagic acid suspension is 0.1 mg / mL-0.5 mg / mL, and the concentration of the fucose solution is 0.5 mg / mL-2.0 mg / mL. The reaction is fully carried out by regulating the concentrations of the ellagic acid suspension and the fucose solution. Specifically, the concentration of the ellagic acid suspension can be 0.1 mg / mL, 0.2 mg / mL, 0.3 mg / mL, 0.4 mg / mL, 0.5 mg / mL, etc., and the concentration of the fucose solution can be 0.5 mg / mL, 1.0 mg / mL, 1.5 mg / mL, 2.0 mg / mL, etc.

[0037] S2, mixing, ball milling, solvent removal

[0038] The ellagic acid suspension and the fucus polysaccharide solution are mixed and stirred to obtain a milky white mixed solution, the mixed solution is ball-milled, and then the solvent in the mixed solution is removed.

[0039] In some embodiments, the mass ratio of ellagic acid to fucan is 1:(0.2-5); preferably 1:(0.3-3), and the amount of ellagic acid and fucan involved in the reaction is optimized to further improve the solubility of ellagic acid. Specifically, the mass ratio of ellagic acid to fucan can be 1:0.2, 1:0.3, 1:0.5, 1:1.0, 1:2.0, 1:3.0, 1:4.0, 1:5.0, etc.

[0040] In some embodiments, the process of preparing a mixed solution includes: mixing and stirring a ellagic acid suspension and a fucan polysaccharide solution at 40°C-50°C for 2h-6h, and through physical impact, shearing and other treatments, ellagic acid and fucan polysaccharide collide to form a non-covalent chemical bond, and the reaction temperature is controlled to allow the reaction to proceed fully.

[0041] Specifically, the stirring temperature can be 40°C, 42°C, 45°C, 48°C, 50°C, etc., and the stirring time can be 2h, 4h, 6h, etc. In the actual operation process, the ellagic acid suspension can be treated in a water bath at 40°C-50°C for 30min, and after the temperature is stable, the fucus polysaccharide solution is poured into the ellagic acid suspension and reacted under stirring.

[0042] In some embodiments, ultrasound assistance is performed during the stirring process, and the ultrasonic power is controlled to be 100W-300W. The rate of compounding can be accelerated by introducing an ultrasonic device to perform water-insulated ultrasonic treatment on the mixed solution until the solution turns milky white, and the ultrasonic treatment is stopped. Specifically, the ultrasonic power can be 100W, 150W, 200W, 250W, 300W, etc.

[0043] In some embodiments, the mixed solution is first ball-milled, and then the solvent in the mixed solution is removed, and the uniformity of the product is improved by ball milling to obtain a product with a smaller particle size. The ball milling speed is controlled to be 100 rpm-200 rpm, and the ball milling time is 2h-6h. By adjusting the ball milling speed and time, the product distribution is made more uniform.

[0044] Specifically, the rotation speed of the ball mill can be 100 rpm, 150 rpm, 200 rpm, etc., and the ball milling time can be 2 h, 4 h, 6 h, etc.

[0045] In some embodiments, the solvent in the mixed solution may be removed by rotary evaporation, but the method is not limited to rotary evaporation, and other methods may also be used to remove the solvent.

[0046] Further, the solid material obtained after removing the solvent is dried, and then the obtained fucose-ellagic acid solid dispersion is sieved, and the water content is reduced by drying, and a product with a particle size that meets the requirements is obtained after sieving. In some embodiments, the drying temperature is controlled to be 40°C-60°C, and the drying time is 4h-10h, and the drying time can be 4h, 6h, 8h, 10h, etc. The mesh number of the sieve during sieving can be 200 meshes, but is not limited thereto, and can be adjusted according to the particle size requirements of the product.

[0047] The embodiment of the present invention provides a fucan-ellagic acid solid dispersion, which is obtained by reacting a carrier and ellagic acid, wherein the carrier is fucan. By preparing the fucan-ellagic acid solid dispersion, the solubility and dispersibility of ellagic acid in water can be significantly improved.

[0048] The embodiments of the present invention also provide the use of the above-mentioned fucose polysaccharide-ellagic acid solid dispersion in improving the ability of ellagic acid to be converted into urolithin or in solubilizing ellagic acid.

[0049] In some embodiments, the ability of the dispersion to improve the conversion of ellagic acid into urolithin can be verified by in vitro fermentation. Specifically, in vitro fermentation is to use the solid dispersion of fucose-ellagic acid as a culture medium, inoculate fecal bacterial liquid for anaerobic fermentation, and control the fermentation time to 3 days to 7 days (such as 3 days, 5 days, 7 days, etc.), thereby obtaining ellagic acid and its conversion products.

[0050] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0051] Example 1

[0052] This embodiment provides a method for preparing a solid dispersion of fucus polysaccharide-ellagic acid, wherein the solid dispersion is prepared by ball milling, and the specific steps are as follows:

[0053] Weigh 20 mg of fucus vesiculosus polysaccharide and 100 mg of ellagic acid (the mass ratio of ellagic acid to fucus vesiculosus polysaccharide is 5:1) respectively and place them in a beaker, add 200 mL of water, pour into a ball mill, add ball mill beads (diameter 3, 5, 8, 10 mm, load 500 g), ball mill at 150 rpm for 3 hours, remove the solution by rotary evaporation, scrape out the powder, take out after grinding, place it in a vacuum drying oven at 50°C and dry it for 6 hours, then sieve the dried product to obtain a ball-milled solid dispersion (named: milling 5:1).

[0054] Example 2

[0055] The only difference from Example 1 is that the mass ratio of ellagic acid to fucus polysaccharide is 3:1. 33.33 mg of fucus polysaccharide and 100 mg of ellagic acid are weighed and placed in a beaker, and 200 mL of water is added. The remaining steps are referred to Example 1 to obtain an ellagic acid solid dispersion with a drug-carrier ratio of 3:1 (named: milling 3:1).

[0056] Example 3

[0057] The only difference from Example 1 is that the mass ratio of ellagic acid to fucus polysaccharide is 1:1. 100 mg of fucus polysaccharide and 100 mg of ellagic acid were weighed and placed in a beaker and 200 mL of water was added. The remaining steps were referred to Example 1 to obtain a solid dispersion of ellagic acid with a drug-carrier ratio of 1:1 (named:

[0058] milling 1:1).

[0059] Example 4

[0060] The only difference from Example 1 is that the mass ratio of ellagic acid to fucus polysaccharide is 1:3. 300 mg of fucus polysaccharide and 100 mg of ellagic acid are weighed and placed in a beaker and 200 mL of water is added. The remaining steps are referred to Example 1 to obtain a ellagic acid solid dispersion with a drug-carrier ratio of 1:3 (named:

[0061] milling 1:3).

[0062] Example 5

[0063] The only difference from Example 1 is that the mass ratio of ellagic acid to fucus polysaccharide is 1:5. 500 mg of fucus polysaccharide and 100 mg of ellagic acid were weighed and placed in a beaker and 200 mL of water was added. The remaining steps were referred to Example 1 to obtain a solid dispersion of ellagic acid with a drug-carrier ratio of 1:5 (named:

[0064] milling 1:5).

[0065] Example 6

[0066] This example provides a method for preparing a solid dispersion of fucus polysaccharide-ellagic acid, wherein a solid dispersion (abbreviated as SD) is prepared by ultrasonic treatment in combination with a solvent-ball milling method, wherein the mass ratio of ellagic acid to fucus polysaccharide is 5:1, and the specific steps are as follows:

[0067] Weigh 20 mg of Fucus polysaccharide and place it in a beaker, add 40 mL of water to the beaker, stir for half an hour, and obtain Fucus polysaccharide solution. Weigh 100 mg of ellagic acid, place it in a beaker equipped with 200 mL of ethanol solution (concentration of 60%), stir for half an hour, and obtain ellagic acid suspension. Pour the Fucus polysaccharide solution into the ellagic acid suspension, keep stirring in a water bath at 45 ° C and use ultrasonic assisted treatment for 3 hours, pour the solution into a ball mill, add ball milling beads, ball mill at 150 rpm for 3 hours, remove the solution using rotary evaporation, scrape out the powder, take out after grinding and place in a vacuum drying oven at 50 ° C for 6 hours, then sieve the dried product to obtain a drug-carrying ratio of 5: 1 ellagic acid solid dispersion (abbreviated EA / FVP5: 1).

[0068] Example 7

[0069] The only difference from Example 6 is that the mass ratio of ellagic acid to fucose is 3:1. Weigh 33.33 mg of fucose and place it in a beaker, add 50 mL of water to the beaker, stir for half an hour, and obtain a fucose solution. Weigh 100 mg of ellagic acid, place it in a beaker containing 200 mL of ethanol solution (concentration of 60%), stir for half an hour, and obtain an ellagic acid suspension. The remaining steps refer to Example 6 to obtain an ellagic acid solid dispersion with a drug-carrying ratio of 3:1 (abbreviated EA / FVP3:1).

[0070] Example 8

[0071] The only difference from Example 6 is that the mass ratio of ellagic acid to fucose is 1:1. Weigh 100 mg of fucose and place it in a beaker, add 100 mL of water to the beaker, stir for half an hour, and obtain a fucose solution. Weigh 100 mg of ellagic acid, place it in a beaker containing 500 mL of ethanol solution (concentration of 60%), stir for half an hour, and obtain an ellagic acid suspension. The remaining steps refer to Example 6 to obtain an ellagic acid solid dispersion with a drug-carrying ratio of 1:1 (abbreviated EA / FVP1:1).

[0072] Example 9

[0073] The only difference from Example 6 is that the mass ratio of ellagic acid to fucose is 1:3. Weigh 300 mg of fucose and place it in a beaker, add 150 mL of water to the beaker, stir for half an hour, and obtain a fucose solution. Weigh 100 mg of ellagic acid, place it in a beaker containing 200 mL of ethanol solution (concentration of 60%), stir for half an hour, and obtain an ellagic acid suspension. The remaining steps refer to Example 6 to obtain an ellagic acid solid dispersion with a drug-carrying ratio of 1:3 (abbreviated EA / FVP1:3).

[0074] Example 10

[0075] The only difference from Example 6 is that the mass ratio of ellagic acid to fucose is 1:5. Weigh 500 mg of fucose and place it in a beaker, add 250 mL of water to the beaker, stir for half an hour, and obtain a fucose solution. Weigh 100 mg of ellagic acid, place it in a beaker containing 200 mL of ethanol solution (concentration of 60%), stir for half an hour, and obtain an ellagic acid suspension. The remaining steps refer to Example 6 to obtain an ellagic acid solid dispersion with a drug-carrying ratio of 1:5 (abbreviated EA / FVP1:5).

[0076] Comparative Example 1

[0077] This comparative example provides a method for preparing a physical mixture of ellagic acid and fucan polysaccharide, wherein the mass ratio of ellagic acid to fucan polysaccharide is 5:1, and the specific steps are as follows: 100 mg of ellagic acid and 20 mg of fucan polysaccharide are weighed and physically mixed to obtain an ellagic acid-fucan polysaccharide mixture with a drug-carrier ratio of 5:1 (abbreviated as 5:1).

[0078] Comparative Example 2

[0079] The only difference from Comparative Example 1 is that the mass ratio of ellagic acid to fucan is 3: 1. 100 mg of ellagic acid and 33.33 mg of fucan were weighed and physically mixed to obtain an ellagic acid-fucan mixture with a drug-carrier ratio of 3: 1 (abbreviated as 3: 1).

[0080] Comparative Example 3

[0081] The only difference from Comparative Example 1 is that the mass ratio of ellagic acid to fucan is 1: 1. 100 mg of ellagic acid and 100 mg of fucan were weighed and physically mixed to obtain an ellagic acid-fucan mixture with a drug-carrier ratio of 1: 1 (abbreviated as 1: 1).

[0082] Comparative Example 4

[0083] The only difference from Comparative Example 1 is that the mass ratio of ellagic acid to fucan is 1:3. 100 mg of ellagic acid and 300 mg of fucan were weighed and physically mixed to obtain an ellagic acid-fucan mixture with a drug-carrier ratio of 1:3 (abbreviated as 1:3).

[0084] Comparative Example 5

[0085] The only difference from Comparative Example 1 is that the mass ratio of ellagic acid to fucan is 1:5. 100 mg of ellagic acid and 500 mg of fucan were weighed and physically mixed to obtain an ellagic acid-fucan mixture with a drug-carrier ratio of 1:5 (abbreviated as 1:5).

[0086] Test Example 1

[0087] The equilibrium solubility of the solid dispersions prepared by ball milling method in Examples 1-5, ultrasonic treatment and solvent-ball milling method in Examples 6-10, and the physical mixtures in Comparative Examples 1-5 were tested. The results are as follows: Figure 1 shown. Figure 1 The letters ah in the middle represent significant differences in the data, and the same letters mean there is no statistical difference.

[0088] Test method: (1) Weigh 1 mg EA and add 1 mL NMP to prepare 1 mg / mL ellagic acid as the mother solution, dilute 10 times, 0.1 mg / mL, inject samples at different contents, and draw a standard curve for ellagic acid. (2) Add the sample (containing 5 mg ellagic acid) to 5 mL pure water, place it in an oscillating water bath and oscillate at a speed of 100 r / min for 6 hours to dissolve the solution and the sample, let it stand for 30 minutes to allow the undissolved sample to settle to the bottom, draw 200 μL of the supernatant, and add 4 times the amount of NMP. After vortexing, filter through a 0.22 μm PTFE membrane filter and measure it by HPLC. Determine the peak area and obtain the equilibrium solubility of each sample in water.

[0089] Depend on Figure 1 It can be seen that, compared with the solubility of ellagic acid, the equilibrium solubility of the physical mixture of ellagic acid and fucan in water is about 0.12 mg / mL, and the solubility has not increased; the equilibrium solubility of the dispersion prepared by ball milling is 0.17 mg / mL-0.56 mg / mL, and after ultrasonic treatment and solvent-ball milling to prepare SD, its solubility in water is significantly improved, reaching 0.72 mg / mL. It can be seen that there are significant differences between different preparation methods and different proportions. The reason may be that the use of fucan is a non-crystalline polymer with high water solubility. During the stirring and ultrasonic process, ellagic acid enters the molecular gap of fucan in the form of fine crystals. Under the obstruction of fucan molecules, EA crystals cannot aggregate. Compared with the single ball milling method, the solvent-ball milling method makes the surface of ellagic acid rough and porous, thereby increasing its surface area and reducing the crystallinity, and improving the solubility of EA in water. The composite method is more effective. When the dispersion was prepared by ultrasonic treatment synergistic solvent-ball milling method, the ratios of ellagic acid and Fucus vesiculosus were 0.17 mg / mL and 0.46 mg / mL, respectively, when they were 5:1 and 1:5, which were worse than the SD with a ratio of 3:1-1:3. Therefore, it can be concluded that ultrasonic treatment synergistic solvent-ball milling method is better than the ball milling method, and the optimal ratio is 3:1-1:3.

[0090] Test Example 2

[0091] The water dispersibility and stability of the products prepared in the test examples were compared, and the solubility and dispersibility of ellagic acid, physical mixing of fucan and ellagic acid, preparation of fucan and ellagic acid solid dispersions by ball milling, and preparation of fucan-ellagic acid solid dispersions by ultrasonic treatment and solvent-ball milling were compared. The results are shown in Table 1.

[0092] Test method: All samples were dissolved in pure water at a concentration of 0.1% (w / v). After being fully mixed with a vortex machine for 1 minute, the OD 600 values ​​(A) of the supernatant at 0, 30, 60, 90, 120, and 150 minutes were recorded, and the absorbance value at 0 minute was expressed as A0.

[0093] Table 1 Stability of solid dispersions prepared by physical mixing, ball milling and ultrasonic treatment of ellagic acid, fucus polysaccharide and ellagic acid, and solvent-ball milling

[0094]

[0095] As can be seen from Table 1, the retention rate of ellagic acid and physical mixture group after 150 minutes is about 47%-50%, indicating that physical mixing cannot improve the stability and dispersibility of ellagic acid. The retention rate of the dispersion prepared by ball milling is 65%-70%, while the stability of the solid dispersion prepared by ultrasonic treatment and solvent-ball milling is better, and the retention rate within 150 minutes fluctuates around 90%, and can be dispersed in aqueous solution for a long time. Retention rate formula:

[0096]

[0097] Test Example 3

[0098] The biotransformation ability of ellagic acid, physical mixing of fucan and ellagic acid, preparation of fucan and ellagic acid solid dispersion by ball milling, and preparation of fucan-ellagic acid solid dispersion by ultrasonic treatment and solvent-ball milling were tested. The results are as follows Figure 2 The letters ae in the figure represent significant differences in the data, and the same letters represent no statistical difference.

[0099] Test method: First, prepare the basic anaerobic nutrient medium: 7.4 g brain heart infusion (BHI), 0.125 g L-cysteine, 30 μL 1.0 mg / mL resazurin solution, and 200 mL water. Add the sample (the final mass concentration of EA is 1 mg / mL) to the basic medium. All media were prepared under anoxic conditions, and the atmosphere consisted of N 2 / H 2 / CO 2(80:10:10), at 37°C, and dispense 9 mL into glass anaerobic tubes. Autoclave the separation medium at 121°C for 20 minutes. Mix equal amounts of fecal samples, homogenize with sterile saline (feces: saline = 1:9 (w / v)), and then filter with sterile gauze. Add 1 mL of fecal suspension to the above sterile medium.

[0100] Samples were collected after 6 days of fermentation to study the product analysis during EA fermentation. In brief, 5 mL of the sample was extracted with 10 mL of ethyl acetate acidified with 1.5% formic acid. The mixture was vortexed thoroughly for 1 minute and centrifuged at 3500 rpm for 8 minutes. 4 mL of the supernatant was drawn and evaporated to dryness to remove the organic reagent. Then 1 mL of NMP was added to the dry sample to dissolve the metabolites. 1 mg of urolithin A was weighed and added to 1 mL of nitrogen-methylpyrrolidone to make 1 mg / mL urolithin A as the mother solution, which was diluted 10 times to 0.1 mg / mL. Samples were injected at different contents to draw a standard curve of urolithin A. The fermentation product and the urolithin A standard were subjected to high-performance liquid chromatography analysis to obtain the content of ellagic acid converted to urolithin A.

[0101] like Figure 2 As shown, it can be seen that there is no significant difference in the conversion between EA and physical mixture, while the dispersion prepared by ball milling is slightly higher than the physical mixture group, at about 1.20μM. The content of urolithin A converted to SD prepared by ultrasonic treatment and solvent-ball milling method is higher than EA's 1.13μM, and the urolithin A in the EA / FVP1:3 group is the highest, reaching 2.37μM. There is no significant difference in the content of the product between EA and the physical mixture group, proving that the increase in SD product is not due to the addition of FVP, but to the improvement of its solubility and dispersibility, and the longer suspension time of the solution, which increases the contact between microorganisms and samples and enhances their biotransformation.

[0102] Based on the experimental results of Examples 1-3, it can be concluded that the use of Fucus vesiculosus polysaccharide-ellagic acid solid dispersion for in vitro fermentation can improve the ability of ellagic acid to be converted into urolithin A.

[0103] In summary, the present invention provides a fucus polysaccharide-ellagic acid solid dispersion and a preparation method and application thereof. The ellagic acid solid dispersion is prepared by ultrasonic treatment in conjunction with a solvent-ball milling method. The preparation process is simple and inexpensive, and the ability of ellagic acid to be converted into urolithin A is greatly improved.

[0104] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A fucus polysaccharide-ellagic acid solid dispersion, characterized in that: It is obtained by compounding a carrier and ellagic acid, wherein the carrier is fucus polysaccharide; The mass ratio of ellagic acid to fucus polysaccharide is 1:(0.2-5); The preparation process of the fucan polysaccharide-ellagic acid solid dispersion comprises: respectively mixing ellagic acid and fucan polysaccharide with a solvent to obtain an ellagic acid suspension and a fucan polysaccharide solution, mixing the ellagic acid suspension and the fucan polysaccharide solution, stirring under ultrasonic-assisted conditions, and then ball milling, and removing the solvent after ball milling to obtain a powdered solid material; The fucus polysaccharide is obtained by water extraction and purification of fucus, and meets the following characteristics: Features (1): Mainly →4)- β -D-Manp-(1→、→3)- α -D-Fucp-(1→、 α -D-Manp-(1→、→3)- β -D-Manp-(1→and→4,6)- α -D-Manp-(1→glycosidic bond composition; Feature (2): The total sugar content is 90%-99%, among which the main monosaccharides are fucose, xylose, mannose, glucuronic acid, glucose and galactose; Feature (3): The average molecular weight is 30-35 kDa.

2. The fucose-ellagic acid solid dispersion according to claim 1, characterized in that: The mass ratio of ellagic acid to fucus polysaccharide is 1:(0.3-3).

3. A method for preparing the fucan-ellagic acid solid dispersion according to any one of claims 1 to 2, characterized in that: include: The ellagic acid and fucan polysaccharide are respectively mixed with a solvent to obtain an ellagic acid suspension and a fucan polysaccharide solution, the ellagic acid suspension and the fucan polysaccharide solution are mixed and stirred under ultrasonic-assisted conditions, and then ball-milled, and the solvent is removed after ball-milling to obtain a powdered solid material; The fucus polysaccharide is obtained by water extraction and purification of fucus, and meets the following characteristics: Features (1): Mainly →4)- β -D-Manp-(1→、→3)- α -D-Fucp-(1→、 α -D-Manp-(1→、→3)- β -D-Manp-(1→and→4,6)- α -D-Manp-(1→glycosidic bond composition; Feature (2): The total sugar content is 90%-99%, among which the main monosaccharides are fucose, xylose, mannose, glucuronic acid, glucose and galactose; Feature (3): The average molecular weight is 30-35 kDa.

4. The preparation method according to claim 3, characterized in that: The ellagic acid suspension and the fucus polysaccharide solution are mixed and stirred at 40° C.-50° C. for 2 h-6 h.

5. The preparation method according to claim 4, characterized in that: During the stirring process, the ultrasonic power was controlled to be 100W-300W.

6. The preparation method according to claim 3, characterized in that: The concentration of the ellagic acid suspension is 0.1 mg / mL-0.5 mg / mL, and the concentration of the fucus polysaccharide solution is 0.5 mg / mL-2.0 mg / mL.

7. The preparation method according to claim 6, characterized in that: The solvent used in preparing the fucus polysaccharide solution is water; the solvent used in preparing the ellagic acid suspension is an ethanol aqueous solution, and the volume fraction of ethanol in the ethanol aqueous solution is 40%-70%.

8. The preparation method according to claim 3, characterized in that: The ball milling speed was controlled at 100 rpm-200 rpm and the ball milling time was controlled at 2 h-6 h.

9. The preparation method according to claim 3, characterized in that: The solvent was removed by rotary evaporation.

10. The preparation method according to claim 3, characterized in that: The powdered solid material is dried and then sieved to obtain the fucan-ellagic acid solid dispersion.

11. The preparation method according to claim 10, characterized in that: Control the drying temperature to 40℃-60℃ and the drying time to 4h-10h.

12. Use of the fucan-ellagic acid solid dispersion according to any one of claims 1 to 2 or the fucan-ellagic acid solid dispersion prepared by the preparation method according to any one of claims 3 to 11 in improving the ability of ellagic acid to be converted into urolithin A or in solubilizing ellagic acid.

13. An ellagic acid product, characterized in that: The invention comprises the fucan polysaccharide-ellagic acid solid dispersion according to any one of claims 1 to 2 or the fucan polysaccharide-ellagic acid solid dispersion prepared by the preparation method according to any one of claims 3 to 11.